A Study of Buntanetap in Participants With PD
← catalyst calendarNCT07284784 · readout ≤ 1,137 d
Sponsored by Annovis Bio Inc. (industry) · ANVS — their whole pipeline →. With Duke Clinical Research Institute.
Phase
Phase 2/3
Status
Recruiting
Study type
Interventional
Design
Non randomized · None · Treatment
Enrollment
500estimated
Sites
27
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2026-01-09 | actual | When the study began enrolling |
| Primary completion | Sep 2029 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Nov 2029 | estimated | The whole study's end, after follow-up |
| First posted | 2025-12-16 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-07-21 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Parkinson's Disease (PD)
- Deep Brain Stimulation
Intervention
- Drug: buntanetap/posiphen
Primary outcomes
what the primary-completion date above is the date OFSafety of buntanetap
measured 36-months of treatment
Adverse Events (AE)
measured 36-months of treatment
Treatment Emergent Adverse Events (TEAE)
measured 36-months of treatment
Serious Adverse Events (SAE)
measured 36-months of treatment
Permalink · ANVS's whole pipeline · Catalyst calendar · Every registered study · What changed